ClinicalTrials.gg
Status unknownNCT03403140Updated Jan 23, 2018

Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )

A Phase 3 interventional study of Etanercept in Rheumatoid Arthritis, sponsored by Gema Biotech S.A.. Status unknown at 1 site in Argentina. Open to participants aged 19 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Gema Biotech S.A. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2016, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
141
Allocation
Not applicable
Ages
19 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing etanercept in Arthritis, Rheumatoid — 4 open to participants now, 5 under way, 1 of them phase 3. Etanercept · Arthritis, Rheumatoid.

Planned enrollment
36th of 69
141 · median 144
Started
2016
with 2 others
Phase 3
20 of 69
1 open now
Registered
62nd of 69
by date

Among the 69 studies testing etanercept in Arthritis, Rheumatoid, this one is the 36th largest by planned enrollment, is one of 3 that started in 2016, is one of 20 in phase 3, and was the 62nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 69 studies testing etanercept in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About etanercept

Etanercept: first FDA approval 1998 (ENBREL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 19 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing etanercept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to asses the long term efficacy, safety and immunogenicity of ENERCEPTAN® in combination with Methotrexate for the treatment of patients with rheumatoid arthritis up to 104 weeks

Read the detailed description

This is a prospective study, single treatment arm of 72 weeks of duration. Patients who completed the original study GEMENE001 may enroll in the study.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
19 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Having completed the final active treatment visit of the GEMENE001 study, the same day or within 28 days prior to entry in this study.
  2. Women of childbearing age must commit to be using an adequate method of to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of Enerceptan®. Suitable methods of contraception are oral contraceptives, IUDs, bilateral tubal ligation, vasectomy or double barrier methods such as condoms or spermicidal diaphragm, sponge, contraceptive foam or gel, heterosexual abstinence. Men should not conceive up to 12 weeks after stopping the MTX
  3. must be signed before making any study-specific procedure

Exclusion criteria

Exclusion Criteria:

  1. Have temporarily interrupted the product in the final study visit GEMENE001 and, according to the investigator's opinion, this represents an unacceptable risk to the patient whether this participates in the GEMENE002 study.
  2. Simultaneous treatment with other investigational drug or participation in another clinical study that the investigator considers inadvisable.
  3. Women who are pregnant or breastfeeding.
  4. History of lack of response or loss of response to previous therapy with Etanercept in the GEMENE001 study.
  5. Chronic antibiotic therapy, if the investigator considers this may affect the safety of the subject or the assessment of the study results.
  6. Any previous or current serious medical conditions which had appeared during the study GEMENE001 that, in the opinion of the investigator, constitute a for the study treatment, as:
  7. Administration of vaccines:

    1. Subjects who have received a within 3 months prior to the selection Visit (for example, varicella-zoster, oral polio, rabies, yellow fever vaccines.)
    2. Subjects who have received the BCG vaccine within the GEMENE001 study
  8. Presence of :

    a. At the time of the inclusion i. Active infections. ii. Fever (≥38 °C) or active, chronic or recurrent infections that require treatment with antibiotics, antiviral, or anti-fungal drugs within 4 weeks prior to Screening Visit, or history of frequent recurrent infections unacceptable to the investigator's opinion.

    iii. Non-healing infected skin ulcers. b. In the previous time: i. Background of recurrent bacterial, viral, fungal (excluding superficial infections or nail bed mycosis), mycobacterial or other severe infections within the last month previous to selection.

    ii. Hospitalization for infection or Subjects who have received antibiotics intravenously within the last month or orally within the last 2 weeks.

    iii. Subjects with herpes zoster in the last 2 months.

  9. Past history of drug or alcohol abuse within the study GEMENE001.
  10. Any condition that, in the investigator's opinion, would not allow compliance with the guidelines of the study by the patient.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
141 participants (estimated)

Study arms

  • Experimental
    Single arm

    Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week

    Drug: Etanercept

Interventions

  • Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).

    Infections, hematological disorders,.neurologic disorders and malignancies .

    Time frame: 72 weeks

Secondary outcomes

  1. Lab tests alterations [Safety and Tolerability]).

    Serum Hematological and chemistry values

    Time frame: 72 weeks

  2. Local reactions [Safety and Tolerability]).

    Incidence, description and severity of Local Adverse Drug Reactions

    Time frame: 72 weeks

  3. ACR20

    ACR (American College of Rheumatology) 20 The percentage of patients who achieved ACR20 at Week 32 is the primary end point. Signs and symptoms are assessed with a composite rating scale of the ACR (American College of Rheumatology) that includes 7 variables: * Tender Joints Count * Swollen Joints Count * Levels of an acute phase reactant (CRP level) * Patient's assessment of pain * Patient's global assessment of disease activity * Physician's global assessment of disease activity * Patient's assessment of physical function

    Time frame: 20 and 72 Weeks

  4. ACR50

    ACR50 is defined as the percentage of patients who achieve at least 50% improvement in both tender joint count and swollen joint count, and at least 50% improvement in at least 3 of the 5 other assessments.

    Time frame: 20 and 72 Weeks

  5. ACR70

    ACR70 is defined as the percentage of patients who achieve at least 70% improvement in both tender joint count and swollen joint count, and at least 50% improvement in at least 3 of the 5 other assessments.

    Time frame: 20 and 72 Weeks

  6. DAS (Disease activity state)

    It will be measured using the DAS (Disease activity state) 28. DAS28 is a composite score that includes 4 variables: * Tender Joints Count (based on 28 joints) * Swollen Joints Count (based on 28 joints) * Patient's global assessment of disease activity * Marker of inflammation: C REACTIVE PROTEIN

    Time frame: 20 and 72 Weeks

  7. Change in modified van der Heijde Sharp score

    The Sharp method is a composite X-ray scoring system used to assess structural (joint) disease progression in rheumatoid arthritis. The method evaluates both joint erosions (JE) and joint space narrowing (JSN) in bilateral hand and foot joints. The Sharp/van der Heijde method assesses erosions and joint space narrowing separately in the hands and feet, and has a range from 0 to 448. Thirty-two joints in the hands and 12 in the feet are scored for erosions, with a maximum score of five per joint in the hands and 10 per joint in the feet. Joint space narrowing is graded from 0 to 4 in 30 joints in the hands and in 12 joints in the feet. The principal score used in the analyses is the total score, which is the sum of the erosion score and the joint space narrowing score.

    Time frame: 20 and 72 Weeks

  8. Physical function

    Improvement in physical function is assessed by change from baseline in HAQ (Health Assessment Questionnaire).The HAQ-DI (disability index) is composed of 8 categories as follows: dressing and grooming, arising, eating, walking, hygiene, reach, grip and activities, for which there are at least 2 questions by category. The patient will be asked to score how difficult he/she feels it is to perform such activities using a 0 to 3 scoring (0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do). If the patient is using assistance for any of these activities, scoring may be adjusted. For each category, the highest score given for one of the question is attributed to the category. The total score is the sum of all categories' scores divided by the number of answered categories (at least 3 categories should be answered)

    Time frame: 20 and 72 Weeks

  9. Functional Assessment of Chronic Illness Therapy Fatigue scale (FACIT-Fatigue)

    The FACIT-Fatigue is a 13-item questionnaire rated 0 to 4. The patient will be asked to answer to 13 questions rated 0 to 4 (0=not at all, 1=a little bit, 2=some what, 3=quite a bit, 4=very much

    Time frame: 20 and 72 Weeks

  10. Steady state concentration

    Etanercept concentration measure

    Time frame: 20 and 72 Weeks

  11. Immunogenicity

    Antibodies anti-Etanercept measure

    Time frame: 20 and 72 Weeks

07

Study locations

1 site
  • Instituto Medico CER
    Bs As, Argentina
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2016 (actual). Primary completion is estimated for Sep 2018, 23 months after the start.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's planned 23 months is close to that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Jan 18, 2018
StartActual
Oct 6, 2016
Primary completionEst.
Sep 30, 2018
CompletionEst.
Oct 31, 2018
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03403140
Lead sponsor
Gema Biotech S.A.
Collaborators
QUID Quality in Drugs and Devices Latin American Consulting SRL
Responsible party
Sponsor
First posted
Jan 18, 2018
Start date
Oct 6, 2016
Primary completion
Sep 30, 2018 (estimated)
Completion
Oct 31, 2018 (estimated)
Last update
Jan 23, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etanercept

Start the discussion